Are you Dr. Yamashita?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 12 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3626 Torrey View CT
San Diego, CA 92130Phone+1 619-306-2125Fax+1 858-617-7705
Summary
- Dr. Mason Yamashita, MD is a psychiatrist in San Diego, California. He is currently licensed to practice medicine in California.
Education & Training
University of Hawaii, John A. Burns School of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 2001 - 2026
Clinical Trials
- Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
- Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo Start of enrollment: 2018 Feb 27
Publications & Presentations
PubMed
- 68 citationsEmricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With PlaceboCatherine Frenette, Giuseppe Morelli, Mitchell L. Shiffman, R. Todd Frederick, Raymond A. Rubin
Clinical Gastroenterology and Hepatology. 2019-03-01 - 59 citationsEmricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension.Guadalupe Garcia-Tsao, Michael Fuchs, Mitchell L. Shiffman, Brian B. Borg, Nikolaos Pyrsopoulos
Hepatology. 2019-02-01 - 171 citationsSTAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J. Reilley, Patricia McCoon, Carl Cook, Paul Lyne, Razelle Kurzrock
Journal for Immunotherapy of Cancer. 2018-11-16
